How should a sigmoid septum be evaluated and managed?

Sigmoid Septum: Evaluation and Management

A sigmoid septum should be evaluated with transthoracic echocardiography including provocative maneuvers (Valsalva) to assess for dynamic left ventricular outflow tract obstruction (LVOTO), and symptomatic patients with significant obstruction (gradient ≥50 mm Hg) should be treated initially with negative inotropic agents (beta-blockers, then disopyramide), reserving septal reduction therapy for drug-refractory cases at experienced centers.

Understanding Sigmoid Septum

Sigmoid septum represents focal, isolated hypertrophy of the basal interventricular septum (≥13 mm in men, ≥12 mm in women) that exceeds 50% of the mid-septal thickness 1. This anatomical variant differs from typical hypertrophic cardiomyopathy (HCM) in several key ways:

• Patient profile: Older age (mean 73 years), predominantly hypertensive, lower glomerular filtration rates 1
• ECG findings: Fewer repolarization abnormalities and lower Cornell index compared to HCM 1
• Morphology: The bidirectional bulge of the basal septum deforms and narrows the LVOT without affecting the virtual basal ring 2

Critical distinction: While sigmoid septum may appear benign at rest, it can cause dynamic LVOTO in hypercontractile states, leading to cryptogenic exertional dyspnea, angina, or syncope 3, 4.

Diagnostic Evaluation

Initial Assessment

Following the 2024 AHA/ACC HCM guidelines framework 5:

1. Transthoracic echocardiography (TTE) is mandatory for initial evaluation, measuring:

   • Basal septal thickness and morphology
   • Resting LVOT gradient
   • Left ventricular systolic function (typically hypercontractile with fractional shortening >46%) 6
   • Mitral valve anatomy and systolic anterior motion (SAM)

2. Provocative maneuvers are essential when resting gradient <50 mm Hg 5:

   • Valsalva maneuver during echocardiography is critical—many patients show no obstruction at rest but develop significant gradients and SAM with provocation 3, 7
   • Exercise TTE for symptomatic patients without resting/provocable gradient ≥50 mm Hg 5

Differentiating from HCM

When septal thickness ≥15 mm (Type 2 sigmoid septum), cardiac MRI becomes valuable 1:

• Fibrosis location patterns differ between sigmoid septum and HCM
• Helps guide treatment decisions when diagnosis is uncertain
• Consider MRI when clinical, ECG, or echo features are atypical

Management Algorithm

Step 1: Asymptomatic Patients

• No intervention required if asymptomatic with normal exercise capacity 8
• Serial TTE every 1-2 years to monitor for changes 5

Step 2: Symptomatic Patients Without Significant Obstruction

• Optimize management of hypertension and other comorbidities
• Consider alternative causes of symptoms

Step 3: Symptomatic Patients With LVOTO (Gradient ≥50 mm Hg)

Medical therapy first-line 6:

• Beta-blockers initially: Achieve mean gradient reduction of ~41 mm Hg in responders; 80% show symptomatic improvement 6
• Add disopyramide if inadequate response: Provides additional ~24 mm Hg gradient reduction in tolerant patients 6
• Continue guideline-directed medical therapy (GDMT) optimization

Step 4: Drug-Refractory Symptoms (NYHA Class III-IV)

Septal reduction therapy at experienced HCM centers 5, 8:

Surgical myectomy preferred (mortality <1%, success >90-95%):

• Appropriate for broadest range of patients
• Allows gradient relief at any ventricular level
• Eliminates SAM-mediated mitral regurgitation
• Long-term survival similar to age-matched population
• Rare recurrence of obstruction

Alcohol septal ablation alternative 8, 3, 4:

• When surgery contraindicated due to comorbidities/advanced age
• Requires appropriate coronary anatomy
• Avoid if gradient ≥100 mm Hg or septal thickness ≥30 mm
• Higher permanent pacemaker risk and repeat intervention rates
• Lower 10-year survival compared to myectomy

Emerging option - Endocardial radiofrequency ablation 4:

• Case reports show symptom improvement and morphological changes
• Septum reduction from 16 to 13 mm documented at 10 months
• Requires further validation but promising for select patients

Critical Pitfalls to Avoid

1. Missing dynamic obstruction: Always perform Valsalva or exercise provocation—resting studies alone miss many cases 3, 7

2. Premature invasive intervention: Negative inotropes are highly effective (80% symptomatic improvement) and must be optimized first 6

3. Performing septal reduction at low-volume centers: Outcomes are operator and center-dependent; refer to comprehensive HCM centers 8

4. Mitral valve replacement for LVOTO: Should not be performed solely for gradient relief in sigmoid septum 8

5. Assuming benignity: Sigmoid septum can cause significant morbidity when associated with dynamic LVOTO, particularly in hypercontractile states (stress, dehydration, Takotsubo syndrome) 7

Follow-Up Strategy

• Post-medical therapy: Repeat TTE to assess gradient reduction
• Post-septal reduction: TTE at 3-6 months to evaluate procedural results 5
• Long-term: Annual TTE if stable, sooner with clinical status changes 5